Rob Perez or Greg Stea: PLEASE address what's going on at Cubist!

Anonymous

Guest
We need true leadership NOW. The silence thus far from upper management is only exacerbating anger and mistrust in the field. This is not the right time to be letting this situation fester. Most CBMs are barely going through the motions at a time when we should be out there selling our hearts out. At this point, even our customers know something is very wrong at Cubist.

DONT YOU REALIZE HOW DETRIMENTAL THIS ATMOSPHERE IS TO THE BUSINESS?

It isn't blowing over. As a matter of fact the majority won't resign until after our 1st 1/2 year bonuses are paid out. If you hope to salvage this sales force and the launch of Sivextro, you have to take ownership of the situation and present a solution NOW. You've done it before, you can do it again. This needs to come from one of you, not TC, who has lost all credibility with the field.

We're depending on you guys to right the ship. Please don't let us down.
 






Topics: Regulatory
Cubist nears another big antibiotic approval as M&A rumors simmer
August 22, 2014 | By Damian Garde
Lexington, MA's Cubist Pharmaceuticals ($CBST) is inching toward its second drug approval of the year, hoping to win European and U.S. clearance for a new anti-infective as analysts wonder whether the company is in line for a Big Pharma takeout.

The European Medicines Agency has accepted Cubist's application for ceftolozane/tazobactam, a combination antibiotic designed to fight complicated urinary tract and intra-abdominal infections. That sets in motion a review process that will likely wrap up with a yes or no in the second half of next year, the company said. The FDA is already examining the combo product, promising to hand down a final decision by Dec. 21.

If all goes according to plan, the antibiotics-focused Cubist will be gearing up for another big drug launch to follow this summer's approval of Sivextro, a superbug treatment the company picked up in its $707 million deal for Trius Pharmaceuticals last year. That drug is a direct competitor to Pfizer's ($PFE) $1.4 billion-a-year Zyvox, boasting fewer side effects, less frequent dosing and shorter treatment times.

And the biotech's recent run of successes has hardly gone unnoticed, as analysts point out how well its offerings might fit in with some of the world's largest drugmakers. Pfizer, Johnson & Johnson ($JNJ) and Eli Lilly ($LLY) all have the cash and competency to make a run at Cubist, Bloomberg reported, and the biotech is priced to sell. The company commands a market cap of around $4.9 billion, but, considering the promise of its pipeline and the projected growth of its on-the-market Cubicin, that could be an under-valuation, analysts say.

Meanwhile, Cubist is all in on antibiotic R&D, planning to spend about $400 million this year alone in hopes of delivering four new treatments by 2020. Beyond ceftolozane/tazobactam and Sivextro, the company's pipeline includes therapies for hospital-acquired bacterial pneumonia, Clostridium difficile and opioid-induced constipation.

- read the release
- here's Bloomberg's story

Related Articles:
Should deal-needy Pfizer target antibiotics specialist Cubist?
Cubist bounces along with more promising PhIII antibiotic results
Cubist's superbug drug clears FDA panel, lines up for Pfizer
 






We need true leadership NOW. The silence thus far from upper management is only exacerbating anger and mistrust in the field. This is not the right time to be letting this situation fester. Most CBMs are barely going through the motions at a time when we should be out there selling our hearts out. At this point, even our customers know something is very wrong at Cubist.

DONT YOU REALIZE HOW DETRIMENTAL THIS ATMOSPHERE IS TO THE BUSINESS?

It isn't blowing over. As a matter of fact the majority won't resign until after our 1st 1/2 year bonuses are paid out. If you hope to salvage this sales force and the launch of Sivextro, you have to take ownership of the situation and present a solution NOW. You've done it before, you can do it again. This needs to come from one of you, not TC, who has lost all credibility with the field.

We're depending on you guys to right the ship. Please don't let us down.

These guys don't care!! They still think that it's a privilege to work st this shit hole!! Telling us that we need to sell all 4 of these products and start "raising awareness" about gram negative bacteria??? I have news for you all, dr's know ALL about gram negatives, really nice way to have us start promoting CT well before it's approval. FU, I'm not doing that!! So I can have some JO from justice at my door, or even worse, one of the attorneys here telling me that I crossed a boundary! They want us to risk our jobs and bonuses so they can look like heros and continue to cash in on stock options, while we get fkn videos from Tony! Good riddance to you, I'm outta here next week and I'm telling my docs that the company is still going to gouge them on Dapto and dificid.
 






They don't care about us!!!!! Look at how much our leader Gregg made last week off of our backs!!!!!

08/19/2014 STEA, GREGORY Senior Vice President Option Execute 38,326 $21.56 - $42.09 826.3K 56,462

08/19/2014 STEA, GREGORY Senior Vice President Sell 38,326 $65.88 2.5M 18,136

Almost 3.5 million dollars and we're fighting for 40k!!! Thanks a lot guys. FU
 






They don't care about us!!!!! Look at how much our leader Gregg made last week off of our backs!!!!!

08/19/2014 STEA, GREGORY Senior Vice President Option Execute 38,326 $21.56 - $42.09 826.3K 56,462

08/19/2014 STEA, GREGORY Senior Vice President Sell 38,326 $65.88 2.5M 18,136

Almost 3.5 million dollars and we're fighting for 40k!!! Thanks a lot guys. FU

Leadership NO
Cowards Yes
To them it's all about their $$$ you mean nothing.
 






Complaints, complaints, and more complaints with no solutions are not helpful. If I were the King, the primary issues at hand would be dealt with in the following ways.

Issue #1 is the disconnect between the company's success and the level at which the commercial organization participates in reaping the rewards of that success. The answer is profit sharing. A plan might involve providing an annual profit sharing pool of just $4,000,000 to the commercial organization annually, that would represent just 1% of the $400,000,000 that we are currently spending on R&D. This profit sharing pool if divided equally could provide $20,000 each to of the 200 CBMs in the field. Considering this expense would represent less than half of 1% of the annual sales of 1 billion dollars this year, that money would be well spent to allow those that create the sales to share in the company's success. The profit sharing pool would be based on the company's profits. Determination of share amounts could be determined by performance, tenure, or a combination of both.

Issue #2 is that selling 5 products across multiple specialties is too overwhelming. The answer is to re-organize the sales force. This would make the work load more manageable as well as create promotional opportunities for the field.

Issue #3 is that there is no accountability in the market access group and this is creating angst in the field. The answer is that the bonus structure of the SAM team should be tied to the specific accounts or systems that they are responsible for. It is illogical that a SAM should get credit for sales that they had nothing to do with. Similar accountability issues exist with the CSD team, they need to do some housecleaning over there.

Issue #4 is that the sales goals have been unreasonably high in the past few years resulting in payouts that are substantially lower than our target payout. The answer is to fire those that come up with these absurd sales goals and get someone that is competent at forecasting to come up with the goals. The target bonus of 40k is very fair if we actually have a chance to hit it.

Issue #5 is that the level of admin has become excessive. the answer is that if you take care of issues #1 thru #4 then we won't care about issue #5.

I would take time to let the field know how important they are to the future success of Cubist as well as address some of the concerns listed above in a town hall type discussion with the field.

Just sayin' ......that's what I would do if I were King. Oh, and I'd also give myself a raise. Talk to you know who about this.

P.S.
Let's stop the brutally negative posting on this board, it's not helpful and does not create an environment where our leaders want to help us. Instead, it makes them question what type of employees we have out there working for them. Be constructive and not destructive, if you have that much anger in your heart then it's time to move on. None of the answers above will heal your wounds.
 


















Complaints, complaints, and more complaints with no solutions are not helpful. If I were the King, the primary issues at hand would be dealt with in the following ways.

Issue #1 is the disconnect between the company's success and the level at which the commercial organization participates in reaping the rewards of that success. The answer is profit sharing. A plan might involve providing an annual profit sharing pool of just $4,000,000 to the commercial organization annually, that would represent just 1% of the $400,000,000 that we are currently spending on R&D. This profit sharing pool if divided equally could provide $20,000 each to of the 200 CBMs in the field. Considering this expense would represent less than half of 1% of the annual sales of 1 billion dollars this year, that money would be well spent to allow those that create the sales to share in the company's success. The profit sharing pool would be based on the company's profits. Determination of share amounts could be determined by performance, tenure, or a combination of both.

Issue #2 is that selling 5 products across multiple specialties is too overwhelming. The answer is to re-organize the sales force. This would make the work load more manageable as well as create promotional opportunities for the field.

Issue #3 is that there is no accountability in the market access group and this is creating angst in the field. The answer is that the bonus structure of the SAM team should be tied to the specific accounts or systems that they are responsible for. It is illogical that a SAM should get credit for sales that they had nothing to do with. Similar accountability issues exist with the CSD team, they need to do some housecleaning over there.

Issue #4 is that the sales goals have been unreasonably high in the past few years resulting in payouts that are substantially lower than our target payout. The answer is to fire those that come up with these absurd sales goals and get someone that is competent at forecasting to come up with the goals. The target bonus of 40k is very fair if we actually have a chance to hit it.

Issue #5 is that the level of admin has become excessive. the answer is that if you take care of issues #1 thru #4 then we won't care about issue #5.

I would take time to let the field know how important they are to the future success of Cubist as well as address some of the concerns listed above in a town hall type discussion with the field.

Just sayin' ......that's what I would do if I were King. Oh, and I'd also give myself a raise. Talk to you know who about this.

P.S.
Let's stop the brutally negative posting on this board, it's not helpful and does not create an environment where our leaders want to help us. Instead, it makes them question what type of employees we have out there working for them. Be constructive and not destructive, if you have that much anger in your heart then it's time to move on. None of the answers above will heal your wounds.

Spot on great post well thought out. If Mike & Rob cared they would print this post off and see what they could do but...they don't care!!! Great post anyway & thank you.
 






A truly great post! What is your email so I can thank you! If they took a close look at these points, everything would be so much better! We already have great products!
 
























This is all fine and Dandy but I keep hearing the new VP who was at Cubist, is helping Medco pluck his home boys away from Cubist like crazy. They are real turds!

You might want to look up the track record of that new VP. He's on his 5th job in 3 years, must have made some great decisions in that time. Be careful who you follow!
 






You are all delusional. Best of the best? You are all 3rd and 4th generation Cubist reps. Get over yourselves. TMC will find out real fast they just over paid for replacements of the replacements of the replacements.

Translation: You didn't get an offer from TMC. Sorry to hear that you are stuck at Cubist where you clearly think you are "underpaid". Best of luck rearranging the chairs on the deck of the Titanic.

Oh, and btw, we at TMC are very aware of your history of price increases. From $70 to $340 in 11 short years? No wonder your upper execs are loaded and don't care if your reps bolt for higher base salaries. That's a lot of profit margin.

I will remind my Directors of Pharmacy of your pricing history. They already LOVE you, Cubist! (wink wink)
 






Topics: Regulatory
Cubist nears another big antibiotic approval as M&A rumors simmer
August 22, 2014 | By Damian Garde
Lexington, MA's Cubist Pharmaceuticals ($CBST) is inching toward its second drug approval of the year, hoping to win European and U.S. clearance for a new anti-infective as analysts wonder whether the company is in line for a Big Pharma takeout.

The European Medicines Agency has accepted Cubist's application for ceftolozane/tazobactam, a combination antibiotic designed to fight complicated urinary tract and intra-abdominal infections. That sets in motion a review process that will likely wrap up with a yes or no in the second half of next year, the company said. The FDA is already examining the combo product, promising to hand down a final decision by Dec. 21.

If all goes according to plan, the antibiotics-focused Cubist will be gearing up for another big drug launch to follow this summer's approval of Sivextro, a superbug treatment the company picked up in its $707 million deal for Trius Pharmaceuticals last year. That drug is a direct competitor to Pfizer's ($PFE) $1.4 billion-a-year Zyvox, boasting fewer side effects, less frequent dosing and shorter treatment times.

And the biotech's recent run of successes has hardly gone unnoticed, as analysts point out how well its offerings might fit in with some of the world's largest drugmakers. Pfizer, Johnson & Johnson ($JNJ) and Eli Lilly ($LLY) all have the cash and competency to make a run at Cubist, Bloomberg reported, and the biotech is priced to sell. The company commands a market cap of around $4.9 billion, but, considering the promise of its pipeline and the projected growth of its on-the-market Cubicin, that could be an under-valuation, analysts say.

Meanwhile, Cubist is all in on antibiotic R&D, planning to spend about $400 million this year alone in hopes of delivering four new treatments by 2020. Beyond ceftolozane/tazobactam and Sivextro, the company's pipeline includes therapies for hospital-acquired bacterial pneumonia, Clostridium difficile and opioid-induced constipation.

- read the release
- here's Bloomberg's story

Related Articles:
Should deal-needy Pfizer target antibiotics specialist Cubist?
Cubist bounces along with more promising PhIII antibiotic results
Cubist's superbug drug clears FDA panel, lines up for Pfizer


Outstanding post. These guys better address things with our nasty lawyers, AG comm bitches and other accounting vultures picking at our bones everyday. TC and GS are a couple of AHs. But Bonney & Perez know we are going to be sold soon so could care less. People are not working a lick here. Wait till after 8/29 when bonus is paid the mass exodus will commence.
 






What till end of this week after we get our bonus. The mass exodus will commence. This place was a lot of fun but has quickly turned into a cesspool. Our nasty lawyers, accounting and AG comm pick at our bones everyday. Senior management could care less they just want to sell Cubist so they can get their money. TC & GS are both evil losers. A very unhealthily environment for all of us.
 






Complaints, complaints, and more complaints with no solutions are not helpful. If I were the King, the primary issues at hand would be dealt with in the following ways.

Issue #1 is the disconnect between the company's success and the level at which the commercial organization participates in reaping the rewards of that success. The answer is profit sharing. A plan might involve providing an annual profit sharing pool of just $4,000,000 to the commercial organization annually, that would represent just 1% of the $400,000,000 that we are currently spending on R&D. This profit sharing pool if divided equally could provide $20,000 each to of the 200 CBMs in the field. Considering this expense would represent less than half of 1% of the annual sales of 1 billion dollars this year, that money would be well spent to allow those that create the sales to share in the company's success. The profit sharing pool would be based on the company's profits. Determination of share amounts could be determined by performance, tenure, or a combination of both.

Issue #2 is that selling 5 products across multiple specialties is too overwhelming. The answer is to re-organize the sales force. This would make the work load more manageable as well as create promotional opportunities for the field.

Issue #3 is that there is no accountability in the market access group and this is creating angst in the field. The answer is that the bonus structure of the SAM team should be tied to the specific accounts or systems that they are responsible for. It is illogical that a SAM should get credit for sales that they had nothing to do with. Similar accountability issues exist with the CSD team, they need to do some housecleaning over there.

Issue #4 is that the sales goals have been unreasonably high in the past few years resulting in payouts that are substantially lower than our target payout. The answer is to fire those that come up with these absurd sales goals and get someone that is competent at forecasting to come up with the goals. The target bonus of 40k is very fair if we actually have a chance to hit it.

Issue #5 is that the level of admin has become excessive. the answer is that if you take care of issues #1 thru #4 then we won't care about issue #5.

I would take time to let the field know how important they are to the future success of Cubist as well as address some of the concerns listed above in a town hall type discussion with the field.

Just sayin' ......that's what I would do if I were King. Oh, and I'd also give myself a raise. Talk to you know who about this.

P.S.
Let's stop the brutally negative posting on this board, it's not helpful and does not create an environment where our leaders want to help us. Instead, it makes them question what type of employees we have out there working for them. Be constructive and not destructive, if you have that much anger in your heart then it's time to move on. None of the answers above will heal your wounds.

Ok Greg your a miserable individual and all your money will not change that. You leave the house for >12 hours a day because they can't stand you out there either!